“The results from the WAYPOINT trial support tezepelumab’s potential as an important new treatment to benefit patients whose lives are disrupted by CRSwNP and may signal that it differs from ...

Tezepelumab (Tezspire) has shown significant clinical benefits in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), including marked reductions in nasal congestion and polyp ...

WAYPOINT is a double-blind, multi-center, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP. 1,2,3 ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The ...

WAYPOINT was a double-blind, multi-centre, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP. 1,2,17 ...

The 52-week, randomized, double-blind, placebo-controlled WAYPOINT trial (ClinicalTrials.gov Identifier: NCT04851964) evaluated the efficacy and safety of tezepelumab in adults with severe CRSwNP.

A mgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire (tezepelumab-ekko) for treating chronic rhinosinusitis with nasal polyps (CRSwNP).

SAN DIEGO — Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to an abstract presented here. Results were seen as early as ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp ...

WAYPOINT was a double-blind, multi-centre, randomised, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP. Participants ...

Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire ...

positive results from tezspire® (tezepelumab-ekko) phase 3 waypoint trial highlight rapid, sustained effect in chronic rhinosinusitis with nasal polyps. published 2:30 pm saturday, march 1, 2025.